MDM2 (MDM2 Proto-Oncogene, E3 Ubiquitin Protein Ligase) is a Protein Coding gene. Diseases associated with MDM2 include dedifferentiated liposarcoma and atypical lipomatous tumor. Among its related pathways are PI3K-Akt signaling pathway and PI3K/AKT Signaling in Cancer. Mdm2 is an important negative regulator of the p53 tumor suppressor. Mdm2 protein functions both as an E3 ubiquitin ligase that recognizes the N-terminal trans-activation domain (TAD) of the p53 tumor suppressor and an inhibitor of p53 transcriptional activation. MDM2 promotes tissue inflammation and MDM2 inhibition has potent anti-inflammatory effects in tissue injury.
References:
See how our premier bioanalytical services support all phases of biomarker, immunogenicity, PK, and cell-based assay studies.
Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.